– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
– Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

– RapidPulse from Miami FL raised $15M in Series A funding.
– The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
– The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.

– Veralox is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
– The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO.
– The new investment will be used to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

– Standard Bariatrics has developed the Titan SGS™, a first-of-its-kind design that offers surgeons performing sleeve gastrectomy, the top bariatric surgical procedure for obesity disease, the industry’s longest continuous staple cutline of 23 centimeters.
– The company today announced the completion of a $35M Series B round led by U.S. Venture Partners (USVP), a Silicon Valley venture capital firm that partners with entrepreneurs to transform their ideas into world-changing companies.
– New investor River Cities Capital joins the Series A syndication investors RiverVest® Venture Partners, Hatteras Venture Partners, Queen City Angels and Emergent Medical Partners who also participated in the Series B round.

– Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA based developer of novel TNF Superfamily antagonist antibodies.
– Company raised $10M Series A/A1 financing.
– Investors included BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments.
– The company intends to use the funds for the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates.

– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
– Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.